PD Neurotechnology® at MDS PAS Congress 2022

3 August 2022

PD Neurotechnology® was present as an exhibitor and a bronze sponsor at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress, held on May 26-28, in Miami Florida, a successful event with more than 400 registrants from 22 countries.0693e3

The  4th Pan American Parkinson’s Disease and Movement Disorders Congress 2022 was a unique opportunity for the company to introduce PDMonitor® to movement disorders specialists from the Americas and officially launch its commercialization pre-sales efforts in the region.

PD Neurotechnology® also organized its first US Medical Advisory Board meeting (MAB), which helped steer the company’s strategy in the US and lay the foundation for the next round of investigator driven clinical studies to prove PDMonitor®’s usefulness in daily practice.

Nikos Moschos, Founder and Business Director of PD Neurotechnology® commented: “It was a pleasure to welcome our booth physicians and industry experts and to present to them how PDMonitor® is driving a paradigm shift in Parkinson’s disease management. The US market presents a major opportunity and we can’t wait to make PDMonitor® available to the market for the benefit of Parkinson’s patients. In this effort, the support of our highly talented and visionary Medical Advisory Board will be insurmountable.”

Discover more about PD Neurotechnology Ltd:

PD Neurotechnology Ltd. is an awarded, high-tech medical device company, founded in London, UK in 2015, certified with ISO 9001:2015, ISO 27001:2013, ISO 27701:2019 and ISO 13485:2016. Its first product, PDMonitor is a CE marked, Class IIa medical device, a digital, noninvasive, continuous monitoring system and management tool, used by patients with Parkinson’s Disease, which enables an accurate motor symptom evaluation, coupled with information on lifestyle and drug adherence. A web application offers the treating physician a comprehensive and objective view of the patient status and supports the assessment of the disease stage and prompt and optimal modification of the treatment. PDMonitor is currently marketed in 10 European countries, soon to be available in the US, post FDA clearance.

Recent posts